Contract facts
SBA(PYP-TC99M ATRIAL AMYLOIDOSIS) CANNOT BE LOCATED ON THE PRICE SCHEDULE FOUND THAT THIS ITEM WAS INADVERTENTLY LEFT OFF THE PRICE LIST is a federal SBA award for 250-Network Contract Office 10 (36C250) held by Schaaf Drugs, LLC. Estimated value —. Related solicitation 36C25023Q0136.
(PYP-TC99M ATRIAL AMYLOIDOSIS) CANNOT BE LOCATED ON THE PRICE SCHEDULE FOUND THAT THIS ITEM WAS INADVERTENTLY LEFT OFF THE PRICE LIST
Incumbent footprint
Public recordSchaaf Drugs, LLC — $3.7M obligated across 18 awards (firm-wide, all agencies).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C25023D0023?
36C25023D0023 (Pyp-tc99m ATRIAL amyloidosis) CANNOT BE located) is a 250-Network Contract Office 10 (36C250) award with an estimated value of —, currently held by Schaaf Drugs, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C250-23-D-0023?
36C250-23-D-0023 is the dashed form of PIID 36C25023D0023 (Pyp-tc99m ATRIAL amyloidosis) CANNOT BE located), held by Schaaf Drugs, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C25023D0023?
250-Network Contract Office 10 (36C250) awarded 36C25023D0023 to Schaaf Drugs, LLC.
Who is the incumbent on 36C25023D0023?
Schaaf Drugs, LLC is the incumbent with $3.7M across 18 related awards in SCOUT’s public footprint.
When does Schaaf Drugs, LLC’s 36C25023D0023 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.